Cargando…

523 Reduced Incidence of Fractures After Treatment with Oxandrolone in Burn Patients

INTRODUCTION: Bone density loss is a significant and well documented complication after major burns. Oxandrolone and bisphosphonates have both been used successfully to mitigate this outcome. Studies show these agents reduce both short-term and long-term bone loss, but no studies have examined the l...

Descripción completa

Detalles Bibliográficos
Autores principales: Walters, Elliot, Whitley, Kayleen, Wolf, Steven E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945503/
http://dx.doi.org/10.1093/jbcr/irac012.154
_version_ 1784673974554198016
author Walters, Elliot
Whitley, Kayleen
Wolf, Steven E
author_facet Walters, Elliot
Whitley, Kayleen
Wolf, Steven E
author_sort Walters, Elliot
collection PubMed
description INTRODUCTION: Bone density loss is a significant and well documented complication after major burns. Oxandrolone and bisphosphonates have both been used successfully to mitigate this outcome. Studies show these agents reduce both short-term and long-term bone loss, but no studies have examined the long-term clinical outcomes of these agents. This study investigates long-term outcomes of treatment with oxandrolone and bisphosphonates in burn patients. METHODS: We examined a deidentified database of electronic medical records across 55 healthcare organizations including over 75 million patients. ICD 10 codes were used to identify patients with thermal or chemical burns from January 1, 2010 to December 31, 2020. We included patients who received their first dose of oxandrolone or bisphosphonate within one month of injury. Propensity score matching was used to balance patient cohorts. ICD 10 and CPT codes were used to evaluate outcomes. RESULTS: We identified 280,367 patients with burn injuries during the study time period. Of these, 903 (0.32%) received at least one dose of oxandrolone and 307 (0.11%) received at least one dose of a bisphosphonate medication within 1 month of injury. Mortality was higher among matched patients receiving oxandrolone (OR: 3.146, CI: 2.224, 4.449) or a bisphosphonate (OR 3.027, CI: 1.8, 5.092). Fracture at any site and fracture of long bones were significantly lower among matched patients who received oxandrolone (OR: 0.704 CI: 0.542, 0.914, OR: 0.689, CI: 0.51, 0.931; respectively) compared to those who did not. No reduction of fractures was seen among patients who received bisphosphonates (p >0.05). Among patients receiving oxandrolone acute kidney failure was increased (OR: 1.941, CI: 1.454, 2.592) compared to those not receiving the medication but chronic kidney failure was reduced (OR: 0.513, CI: 0.351, 0.749). There was no increase in acute or chronic kidney failure among patients receiving a bisphosphonate (p >0.05). Liver injury was not increased among patients receiving either medication (p >0.05). CONCLUSIONS: Oxandrolone and bisphosphonate medications have been well studied and shown to decrease bone density loss after burn injury. Fractures of all bones and specifically long bones were reduced in patients receiving oxandrolone, suggesting that decreased bone catabolism during the acute recovery period may provide long-term injury protection. While we do see an increase in mortality with both of these medications, there is no we do not see any increase in liver failure or chronic kidney failure suggesting that factors unrelated to the administration of these medications are driving the increased mortality and may be related to selection bias. This is the first study to show that oxandrolone decreases the incidence of fractures after burn injury.
format Online
Article
Text
id pubmed-8945503
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-89455032022-03-28 523 Reduced Incidence of Fractures After Treatment with Oxandrolone in Burn Patients Walters, Elliot Whitley, Kayleen Wolf, Steven E J Burn Care Res Clinical Sciences: Nutrition & Metabolism 1 INTRODUCTION: Bone density loss is a significant and well documented complication after major burns. Oxandrolone and bisphosphonates have both been used successfully to mitigate this outcome. Studies show these agents reduce both short-term and long-term bone loss, but no studies have examined the long-term clinical outcomes of these agents. This study investigates long-term outcomes of treatment with oxandrolone and bisphosphonates in burn patients. METHODS: We examined a deidentified database of electronic medical records across 55 healthcare organizations including over 75 million patients. ICD 10 codes were used to identify patients with thermal or chemical burns from January 1, 2010 to December 31, 2020. We included patients who received their first dose of oxandrolone or bisphosphonate within one month of injury. Propensity score matching was used to balance patient cohorts. ICD 10 and CPT codes were used to evaluate outcomes. RESULTS: We identified 280,367 patients with burn injuries during the study time period. Of these, 903 (0.32%) received at least one dose of oxandrolone and 307 (0.11%) received at least one dose of a bisphosphonate medication within 1 month of injury. Mortality was higher among matched patients receiving oxandrolone (OR: 3.146, CI: 2.224, 4.449) or a bisphosphonate (OR 3.027, CI: 1.8, 5.092). Fracture at any site and fracture of long bones were significantly lower among matched patients who received oxandrolone (OR: 0.704 CI: 0.542, 0.914, OR: 0.689, CI: 0.51, 0.931; respectively) compared to those who did not. No reduction of fractures was seen among patients who received bisphosphonates (p >0.05). Among patients receiving oxandrolone acute kidney failure was increased (OR: 1.941, CI: 1.454, 2.592) compared to those not receiving the medication but chronic kidney failure was reduced (OR: 0.513, CI: 0.351, 0.749). There was no increase in acute or chronic kidney failure among patients receiving a bisphosphonate (p >0.05). Liver injury was not increased among patients receiving either medication (p >0.05). CONCLUSIONS: Oxandrolone and bisphosphonate medications have been well studied and shown to decrease bone density loss after burn injury. Fractures of all bones and specifically long bones were reduced in patients receiving oxandrolone, suggesting that decreased bone catabolism during the acute recovery period may provide long-term injury protection. While we do see an increase in mortality with both of these medications, there is no we do not see any increase in liver failure or chronic kidney failure suggesting that factors unrelated to the administration of these medications are driving the increased mortality and may be related to selection bias. This is the first study to show that oxandrolone decreases the incidence of fractures after burn injury. Oxford University Press 2022-03-23 /pmc/articles/PMC8945503/ http://dx.doi.org/10.1093/jbcr/irac012.154 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the American Burn Association. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Sciences: Nutrition & Metabolism 1
Walters, Elliot
Whitley, Kayleen
Wolf, Steven E
523 Reduced Incidence of Fractures After Treatment with Oxandrolone in Burn Patients
title 523 Reduced Incidence of Fractures After Treatment with Oxandrolone in Burn Patients
title_full 523 Reduced Incidence of Fractures After Treatment with Oxandrolone in Burn Patients
title_fullStr 523 Reduced Incidence of Fractures After Treatment with Oxandrolone in Burn Patients
title_full_unstemmed 523 Reduced Incidence of Fractures After Treatment with Oxandrolone in Burn Patients
title_short 523 Reduced Incidence of Fractures After Treatment with Oxandrolone in Burn Patients
title_sort 523 reduced incidence of fractures after treatment with oxandrolone in burn patients
topic Clinical Sciences: Nutrition & Metabolism 1
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945503/
http://dx.doi.org/10.1093/jbcr/irac012.154
work_keys_str_mv AT walterselliot 523reducedincidenceoffracturesaftertreatmentwithoxandroloneinburnpatients
AT whitleykayleen 523reducedincidenceoffracturesaftertreatmentwithoxandroloneinburnpatients
AT wolfstevene 523reducedincidenceoffracturesaftertreatmentwithoxandroloneinburnpatients